多发性硬化症管理中的当前和未来趋势:近东视角
Anmar Hatem1, Nabil K El Ayoubi2, Majed Habahbeh3
1MS Clinic, Baghdad Teaching Hospital, Medical City Complex, Baghdad, Iraq.
Multiple sclerosis and related disorders
|June 12, 2023
概括
中东的神经科医生优先考虑治疗的有效性和安全性,选择受到药物可用性和计划生育等患者特定因素的影响. 需要更多关于多发性硬化症 (MS) 新兴疗法的数据.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 的患病率在中东地区正在增加.
- 该地区的药物可用性可能会影响神经科医生对MS的处方习惯.
- 了解当前的处方实践对于优化多发性硬化护理至关重要.
研究的目的:
- 评估近东 (NE) 医疗保健从业人员对多发性硬化症 (MS) 的当前处方做法.
- 评估COVID-19对神经病学家在MS管理中的处方习惯的影响.
- 探索现有和新兴疾病修饰疗法 (DMT) 对多发性硬化症的未来相关性.
主要方法:
- 从2022年4月到7月进行了一项跨部门在线调查.
- 调查问卷是通过来自五个东北国家的神经病学家的投入而开发的.
- 雪球采样被用来招募98名神经科医生参加这项研究.
主要成果:
- 治疗有效性和安全性之间的平衡是选择多发性硬化疗法的主要因素.
- 患者报告的挑战包括计划生育,成本和副作用的耐受性.
- 干扰素β1a SC是轻度至中度RRMS的首选药物,特别是在计划怀孕或母乳养的妇女中. 对于这些患者来说,不建议使用Fingolimod.
- 纳塔利祖马布,奥克雷祖马布和克拉迪布林在高度活跃的MS中被讨论.
- 超过45%的医生缺乏关于布鲁顿氨酸激酶 (BTK) 抑制剂的信息,用于未来的MS治疗.
结论:
- 东北地区的神经病学家在很大程度上遵循MENACTRIMS对MS治疗的建议.
- 疾病修饰疗法 (DMT) 的可用性显著影响治疗选择.
- 对于新兴的多发性硬化疗法,需要现实数据,长期扩展和比较研究.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Nephrotic Syndrome II : Assessment and Medical Management
10
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
10
Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158
Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K


